Zilretta

Macular Edema, Stomatitis, Denture, Ophthalmia, Sympathetic + 113 more

Treatment

16 FDA approvals

20 Active Studies for Zilretta

Treatment for

Macular Edema

What is Zilretta

TriamcinoloneThe Generic name of this drug

Treatment SummaryTriamcinolone is a steroid used to reduce inflammation in the body from allergies to multiple sclerosis. It can be taken as a one-time treatment for knee pain due to osteoarthritis or used topically to treat skin inflammation. Triamcinolone comes in three forms: hexacetonide, acetonide, and diacetate. The FDA approved the drug in 1957 and in 2021 a new form of triamcinolone was approved for injection to treat macular edema associated with uveitis.

Aristocortis the brand name

Zilretta Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Aristocort

Triamcinolone

1961

532

Approved as Treatment by the FDA

Triamcinolone, also called Aristocort, is approved by the FDA for 16 uses which include Lichen Planus and Ganglia .

Lichen Planus

Helps manage Lichen Planus (LP)

Ganglia

Helps manage cystic tumour of the ganglia

Granuloma Annulare

Helps manage granuloma annulare lesions

Psoriasis

Helps manage Psoriatic plaque

Neurodermatitis

Helps manage Lichen simplex chronicus

Lupus Erythematosus, Discoid

Helps manage Discoid Lupus Erythematosus (DLE)

Keloids Scars

Helps manage Keloids Scars

cystic tumour of the ganglia

Helps manage cystic tumour of the ganglia

Alopecia Areata

Helps manage Alopecia Areata (AA)

granuloma annulare lesions

Helps manage granuloma annulare lesions

Lichen Planus (LP)

Helps manage Lichen Planus (LP)

Psoriatic plaque

Helps manage Psoriatic plaque

Alopecia Areata (AA)

Helps manage Alopecia Areata (AA)

Lichen simplex chronicus

Helps manage Lichen simplex chronicus

Discoid Lupus Erythematosus (DLE)

Helps manage Discoid Lupus Erythematosus (DLE)

Necrobiosis Lipoidica

Helps manage Necrobiosis lipoidica diabeticorum

Effectiveness

How Zilretta Affects PatientsTriamcinolone is a steroid medicine that helps reduce inflammation in different parts of the body. It is not safe to be administered as an epidural injection.

How Zilretta works in the bodyTriamcinolone is a type of corticosteroid that helps reduce inflammation. It does this by stopping certain enzymes from breaking down cell membranes and preventing substances like arachidonic acid from being released. It also helps reduce swelling by reversing the widening of blood vessels and reducing the movement of macrophages and white blood cells. Finally, it stops the production of pro-inflammatory signals like interleukin-6 and monocyte chemoattractant protein-1 by inhibiting nuclear factor kappa-B.

When to interrupt dosage

The proposed dosage of Zilretta is contingent upon the determined condition, for example, Mycosis Fungoides (MF), Mycoses and Alopecia Areata (AA). The amount of dosage is subject to change, in consonance with the delivery approach (e.g. Ointment or Injection, suspension - Intralesional; Parenteral) mentioned in the table beneath.

Condition

Dosage

Administration

Hives

, 40.0 mg/mL, 10.0 mg/mL, 0.055 mg, 0.001 mg/mg, 0.25 mg/mL, 1.0 mg/mL, 0.0005 mg/mg, 0.00025 mg/mg, 0.005 mg/mg, 5.0 mg/mL, 20.0 mg/mL, 0.000147 mg/mg, 0.5 mg/mL, 40.0 mg, 1.0 mg, 0.000025 mg/mg, 0.1 %, 0.025 %, 5.0 mg, 0.25 mg, 2.0 mg, 4.0 mg, 0.5 %, 15.0 mg/mL, 6.5 mg, 80.0 mg/mL, 0.075 mg, 200.0 mg/mL, 32.0 mg, 0.055 mg/dose, 0.5 mg, 0.2 mg/pump actuation, 0.1 mg/dose, 25.0 mg/mL, 0.055 mg/pump actuation, 2.0 mg/mL, 0.4 mg/mL

Injection, suspension - Intra-articular; Intramuscular, Injection, suspension, Intra-articular; Intramuscular, , Intra-articular; Intralesional, Injection, suspension - Intra-articular; Intralesional, Nasal, Spray, metered, Spray, metered - Nasal, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Lotion, Lotion - Topical, Intralesional; Parenteral, Injection, suspension - Intralesional; Parenteral, Intra-articular; Parenteral, Injection, suspension - Intra-articular; Parenteral, Intra-articular; Intrabursal; Intradermal; Intralesional, Injection, suspension - Intra-articular; Intrabursal; Intradermal; Intralesional, Aerosol, spray, Aerosol, spray - Topical, Paste, Paste - Topical, Kit, Injection, suspension - Intramuscular, Intramuscular, Dental, Paste - Dental, Suspension, Suspension - Intra-articular; Intramuscular, Intra-articular; Intrabursal; Intradermal; Intrasynovial, Suspension - Intra-articular; Intrabursal; Intradermal; Intrasynovial, Intra-articular; Intrabursal; Intramuscular, Suspension - Intra-articular; Intrabursal; Intramuscular, Intralesional, Suspension - Intralesional, Aerosol, metered, Aerosol, metered - Nasal, Respiratory (inhalation), Aerosol, metered - Respiratory (inhalation), Intra-articular, Suspension - Intra-articular, Oral, Tablet, Tablet - Oral, Liquid, Intra-articular; Intramuscular; Intrasynovial, Liquid - Intra-articular; Intramuscular; Intrasynovial, Syrup - Oral, Syrup, Intra-articular; Intradermal; Intramuscular, Liquid - Intra-articular; Intradermal; Intramuscular, Suspension - Intramuscular, Intra-articular; Intradermal; Intralesional; Intramuscular, Suspension - Intra-articular; Intradermal; Intralesional; Intramuscular, Spray, suspension - Nasal, Injection, solution, Injection, solution - Intra-articular; Intramuscular, Epidural; Infiltration; Intra-articular; Intramuscular; Topical, Kit - Epidural; Infiltration; Intra-articular; Intramuscular; Topical, Ophthalmic, Injection, suspension - Ophthalmic, Intravitreal, Suspension - Intravitreal, Infiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical, Kit - Infiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical, Spray, Spray - Topical, Intra-articular; Intrasynovial; Periarticular, Suspension - Intra-articular; Intrasynovial; Periarticular, Kit - Intra-articular; Intramuscular, Suspension - Ophthalmic, Subcutaneous, Implant, Implant - Subcutaneous, Epidural; Infiltration; Intra-articular; Intramuscular, Kit - Epidural; Infiltration; Intra-articular; Intramuscular, Intra-articular; Intramuscular; Intravitreal, Injection, suspension - Intra-articular; Intramuscular; Intravitreal, Epidural; Intra-articular; Intramuscular; Topical, Kit - Epidural; Intra-articular; Intramuscular; Topical, Epidural; Infiltration; Intra-articular; Intralesional, Kit - Epidural; Infiltration; Intra-articular; Intralesional, Intra-articular; Intralesional; Intramuscular; Intrasynovial; Parenteral, Injection, suspension - Intra-articular; Intralesional; Intramuscular; Intrasynovial; Parenteral, Kit - Intra-articular, Paste, dentifrice, Paste, dentifrice - Dental, Kit - Infiltration; Soft tissue; Topical, Infiltration; Soft tissue; Topical, Ointment - Buccal, Buccal, Gel, Gel - Topical, Emulsion - Topical, Emulsion, Kit - Topical, Intra-articular; Intramuscular; Topical, Injection, suspension - Intra-articular, Infiltration; Intra-articular; Intramuscular; Topical, Kit - Infiltration; Intra-articular; Intramuscular; Topical

Polymyositis

Asthma

Intertrigo

Necrobiosis Lipoidica

Adrenal Insufficiency

Haemorrhoids

Tennis Elbow

Acne Vulgaris

Craniotomy

Bullous dermatitis herpetiformis

Trichinosis

Brain

Giant Cell Arteritis

Neuralgia, Postherpetic

Dermatitis, Seborrheic

oral lesions

Ulcer

Pyoderma

Itching of the Anus

Warnings

Zilretta Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Triamcinolone may interact with Pulse Frequency

Mycoses

Do Not Combine

active periocular infections

Do Not Combine

Eye Infections

Do Not Combine

There are 20 known major drug interactions with Zilretta.

Common Zilretta Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Triamcinolone is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Triamcinolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Triamcinolone.

Abetimus

Major

The risk or severity of adverse effects can be increased when Triamcinolone is combined with Abetimus.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Triamcinolone.

Zilretta Toxicity & Overdose RiskThe lowest toxic dose of triamcinolone acetonide in rats is 13,100 µg/kg and in mice is 132mg/kg. The oral toxic dose in rats is 1451mg/kg and in mice is 2168mg/kg. The intraperitoneal toxic dose in mice is 105mg/kg. Those who overdose may develop Cushing's Syndrome, which can be treated with supportive therapy and a medicine called mifepristone.

Zilretta Novel Uses: Which Conditions Have a Clinical Trial Featuring Zilretta?

1076 active clinical trials are analyzing the capacity of Zilretta to alleviate Lupus, Atopic Dermatitis and Brain Metastases.

Condition

Clinical Trials

Trial Phases

Ulcer

148 Actively Recruiting

Not Applicable, Phase 1, Phase 3, Phase 2, Phase 4

Asthma

86 Actively Recruiting

Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 1, Phase 3

Ankylosing Spondylitis

3 Actively Recruiting

Phase 3, Not Applicable

Pyoderma

6 Actively Recruiting

Phase 4, Phase 3, Not Applicable, Phase 2

Gingivitis, Necrotizing Ulcerative

0 Actively Recruiting

Rheumatoid Arthritis

52 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Ophthalmia, Sympathetic

0 Actively Recruiting

Dermatitis, Seborrheic

0 Actively Recruiting

Skin

0 Actively Recruiting

Ulcerative Colitis

11 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Tuberculosis

7 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4

Pruritus

0 Actively Recruiting

Haemorrhoids

1 Actively Recruiting

Not Applicable

Wound Infection

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

Thrombocytopenia

0 Actively Recruiting

Dermatitis, Allergic Contact

0 Actively Recruiting

Inflammation

64 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4

Diaper Rash

0 Actively Recruiting

Adrenal Insufficiency

0 Actively Recruiting